Are you looking for a higher-quality, faster-time to market manufacturing solution for your protein therapeutic? Webinar attendees will learn how AbSci and KBI’s partnership enables cell line development through bulk microbial GMP manufacturing in 6 months, using cutting edge cell line development and biomanufacturing technology. Topics covered include:
- E. coli SoluPro® and Protein PrintingTM technologies that enable rapid cell line development for complex protein therapeutics, including bispecifics, cytokines, and difficult-to-express next generation antibody scaffolds.
- Seamless tech transfer of a robust, scalable cell line and fermentation process from AbSci to KBI Biopharma, along with KBI downstream process refinement for robust manufacturing supply
- GMP biopharma manufacturing and release testing at KBI Biopharma’s state of the art manufacturing facilities
- Key CMC enablement activities via KBI Biopharma’s advanced product formulation, analytical characterization and stability program design and expertise